Fundraising Fox
BioReact
Techstars '24Indianapolis, US · Founded 2023 · 8 employees on LinkedIn · 6 known investors
Find your way into BioReact
Sign up to see every warm intro you have to BioReact
- Paths you didn't know you had: your email and LinkedIn already hold routes to the BioReact team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
BioReact provides a data integration platform that unifies experimental data from bioreactors, laboratory instruments, and omics workflows into a standardized, AI-ready format for bioprocess development. The platform serves scientists in synthetic biology, cell therapy, biologics, and precision fermentation who need to consolidate fragmented scientific data for analytics and machine learning.
Also known as BioReact : Bioprocess Meets Ai
Founders & leadership
Investors · 6
How we know: FortySix Venture Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: New Stack Ventures's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: Service Provider Capital's portfolio page · Not right? Tell us
How we know: the Techstars portfolio · open dataset · Top 3000 Accelerator Startups (no YC) 2026-08 · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
Company profile
researched Sep 2026BioReact develops software for bioprocess scientists that consolidates experimental data generated during cell growth in bioreactors and applies statistical and machine-learning analysis to it. The platform ingests and automatically aligns online and offline time-series data from bioreactors, laboratory instruments, offline analyzers and electronic lab notebooks, using a proprietary data harmonization model that interprets structured, semi-structured and unstructured inputs — including experimental measurements, process data, notes, annotations and run metadata — without requiring users to map or preprocess files before upload.
On top of that harmonized data layer, BioReact offers data visualization (heatmaps of process variables), statistical analysis (PCA, ANOVA, factor importance, variation analysis), and AI/ML simulation that predicts conditions for cell growth, yield and viability, running up to 10,000 in-silico experiments per optimization. The company positions the product as a replacement for the combination of ELNs for storage, Excel for organization, tools such as JMP, Minitab and Spotfire for visualization, and a dedicated data scientist for modeling. The platform is offered as a cloud service and can also be deployed on premises, with AWS used for local hosting. The company states that customer data is not rented, sold or otherwise used by BioReact.
Stated application areas include synthetic biology, cell therapy, biologics and precision fermentation, spanning strain engineering, cell line development, process optimization and scale-up, with data connected across bioreactors, omics workflows, downstream processing and process development.
Founding story
Founder and CEO Mitchell Castetter spent years in biotech sales, selling equipment and consumables used in vaccine and biopharmaceutical manufacturing and rising to inside sales manager. Visiting large pharmaceutical customers, he observed that laboratories with advanced equipment lacked effective data flow and infrastructure, with scientists managing millions of data points across hundreds of trials in Excel. Without a coding background himself, he focused on the business side and sought a technical partner, ultimately co-founding the company with Joanna Lipinski, a PhD-level bioinformatics software developer who became CTO and built the cloud-native platform for ingesting terabytes of time-series and omics data. The company was founded in early 2023 to address fragmented scientific data in bioprocess development.
Business model
BioReact sells software to biotechnology and pharmaceutical organizations, delivered as a cloud-based platform that can alternatively be hosted on a customer's own premises (with AWS preferred for local hosting). The product bundles data management, visualization, statistical analysis and AI/ML optimization in a single tool intended to replace several separately purchased software categories.
Traction
The website reports more than 600 scientists using BioReact and cites benchmarking against traditional DOE methodologies with a 22% increase in yield across experiments, outperforming scientist-designed DOE 90% of the time and estimated savings of $440,000 per project. Roughly 15 pilot companies were brought on to train the models. A January 2026 report stated the company had secured $1.1 million in funding to accelerate product development and expand its market reach.
Latest developments
In January 2026 it was reported that BioReact had secured $1.1 million in funding, to be used to refine the platform, add features and expand its market reach within the biotechnology and pharmaceutical sectors.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
BioReact positions itself against the incumbent combination of ELNs, spreadsheets and desktop statistics packages (JMP, Minitab, Spotfire) used in bioprocess data workflows, and benchmarks its optimization results against traditional design-of-experiments methodology. The longer-term stated ambition is to consolidate a fragmented biotech software landscape, in which organizations buy many separate tools, into a single platform, including by acquiring or building adjacent biotech businesses.
Technology
The platform's core is a proprietary data harmonization model that automatically interprets and unifies online data, offline data and associated metadata at ingestion, distinguishing experimental measurements, process data and contextual information such as notes and run metadata. It performs automatic alignment of online and offline time-series data and integrates with major ELNs, bioreactors and offline analyzers, including Sartorius, Infors, Eppendorf and HPLC systems. Analysis capabilities include PCA, ANOVA, factor importance and variation analysis, plus AI/ML simulation supporting up to 10,000 in-silico experiments per optimization. The company reports that its AI is trained on more than 12 million data points covering cell lines including CHO, yeast, Pichia, HEK293 and E. coli, and that models were trained with the help of roughly 15 pilot user companies. The architecture is cloud-native and capable of ingesting terabytes of time-series and omics data; the system is encrypted, and the stored data and the tagging that links it to strain and organism identities are separated so that access to one part does not readily expose the other.
Go-to-market
The founder handles sales and marketing directly, having come from biotech equipment sales. AI and machine learning capabilities are described as the initial hook that brings customers in, after which the data management and visualization functions are adopted. The company recruited approximately 15 pilot companies as early users to help train its models, and its website drives inbound contact through a contact form and meeting booking.
Bioprocess scientists and engineers in biotechnology and pharmaceutical organizations working in synthetic biology, cell therapy, biologics and precision fermentation, covering strain engineering, cell line development, process development and scale-up. End products of the bioprocesses served include cosmetics, cultured meat and pharmaceuticals.
Geography
Headquartered in Indianapolis, Indiana, United States, at 1210 Waterway Blvd Ste 2000. The founder notes that the lower cost of living in Indianapolis extends the company's runway and that increased investor willingness to meet virtually has widened fundraising access outside traditional tech hubs.
History
Founded in early 2023 by Mitchell Castetter, who was joined by co-founder and CTO Joanna Lipinski, PhD. The company built a platform to unify fragmented bioprocess data, onboarded about 15 pilot companies to train its models, and was profiled in Engine's #StartupsEverywhere series in July 2025. Funding of $1.1 million was reported in January 2026.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsBioReact announced it had secured $1.1 million, to be used to accelerate its product development roadmap, introduce new features and expand its market reach in the biotechnology and pharmaceutical sectors.
$1.1M source ↗
Engine published an interview with CEO Mitchell Castetter covering the company's origins in biotech sales, its bioreactor data platform, AI model development with about 15 pilot companies, data security approach, and fundraising in Indianapolis.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 8
primary sources listed
- BioReactbioreact.co · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does BioReact do?
- BioReact is a bioprocess software platform that unifies bioreactor and lab data and applies AI/ML to optimize cell growth conditions.
- Who are BioReact's investors?
- BioReact's investors include FortySix Venture Capital, Hurricane Ventures, New Stack Ventures, Service Provider Capital, Techstars, Firstrock Capital.
- Where is BioReact headquartered?
- BioReact is headquartered in Indianapolis, US.